title: [Advances in the management of renal cell carcinoma].
abstract: Renal cell carcinoma accounts for about 3-4% of all malignancies and its incidence is steadily rising. The article presents in short the rationale behind the targeted therapies and provides an update on current therapeutic approaches to metastatic renal cell carcinoma. It also summarizes the most recent developments in the immunotherapy such as immune checkpoint inhibitors, anti-cancer vaccines and chimeric antigen receptors on T cells.
authors.affiliation: Katedra i Klinika Nefrologii, Dializoterapii i Chorób Wewnętrznych WUM, Warszawa, Polska, jrowinska@gmail.com.
authors.forename: Joanna
authors.initials: J
authors.lastname: Matuszkiewicz-Rowińska
authors.affiliation: Katedra i Klinika Nefrologii, Dializoterapii i Chorób Wewnętrznych WUM, Warszawa, Polska.
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Kościelska
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D058990:Molecular Targeted Therapy
chemical_list: D000911:Antibodies, Monoclonal; D019496:Cancer Vaccines
keywords:  chimeric antigen receptors;  immune checkpoints inhibitors;  molecular-targeted therapy; renal cell carcinoma